The purpose of this study is to identify early immune markers associated with response to
treatment with abatacept in individuals with Type 1 diabetes (T1D). In this open label
mechanistic study, participants who were recently diagnosed with T1D (males or females, ages
6-45 and <7months from T1D diagnosis) will be treated with a short-course of abatacept
(weekly subcutaneous injections for 3 months). Participants will undergo baseline and
repeated mixed meal tolerance testing (MMTT) to assess disease progression and blood samples
will be obtained at frequent intervals to measure changes in immune markers.
Phase:
Early Phase 1
Details
Lead Sponsor:
Carla Greenbaum, MD
Collaborators:
Juvenile Diabetes Research Foundation Medical College of Wisconsin